Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plunged 40.07% in after-hours trading on Thursday following the release of its first-quarter 2025 financial results that fell short of analysts' expectations and a downward revision of its full-year guidance.
The biotechnology company reported a quarterly loss of $(0.36) per share, significantly wider than the analyst consensus estimate of $(0.24). While this represents a 14.29% improvement from the $(0.42) loss per share in the same quarter last year, it still disappointed investors. Revenue for the quarter came in at $49.32 million, missing the analyst forecast of $81.70 million by 39.63%. Despite the miss, this figure marks a substantial increase from the $715,000 reported in the same period last year.
Adding to investor concerns, Iovance revised its fiscal year 2025 total product revenue guidance to $250 million - $300 million, down from previous projections. The company's net income for the quarter stood at a loss of $116.163 million, with operating income at negative $121.221 million. These figures, coupled with the lowered guidance, appear to have shaken investor confidence in the company's near-term growth prospects, leading to the sharp sell-off in extended trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.